BlossomHill Therapeutics, Inc. is a molecule drug design and development company focused on addressing unmet medical needs in oncology and autoimmune diseases. The company is building a deep pipeline of candidates across a range of targets with the aim of making the next leap forward in treatment for patients. The company’s approach to drug design and development first considers the medical need through deep knowledge of the science behind the disease, and then seeks to design a novel chemotype to provide the best chance of success. Headquartered in San Diego, California, BlossomHill Therapeutics is supported by a strong syndicate of leading investors, including Cormorant Asset Management, OrbiMed, Vivo Capital and Colt Ventures.